MX2014011583A - Metodos y composiciones para el tratamiento de la familia de tumores del sarcoma de ewing. - Google Patents

Metodos y composiciones para el tratamiento de la familia de tumores del sarcoma de ewing.

Info

Publication number
MX2014011583A
MX2014011583A MX2014011583A MX2014011583A MX2014011583A MX 2014011583 A MX2014011583 A MX 2014011583A MX 2014011583 A MX2014011583 A MX 2014011583A MX 2014011583 A MX2014011583 A MX 2014011583A MX 2014011583 A MX2014011583 A MX 2014011583A
Authority
MX
Mexico
Prior art keywords
tumors
compositions
methods
treating
sarcoma family
Prior art date
Application number
MX2014011583A
Other languages
English (en)
Inventor
Jeffrey A Toretsky
Milton Lang Brown
Perrer N Tosso
Aykut Uren
Yali Kong
Original Assignee
Univ Georgetown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgetown filed Critical Univ Georgetown
Publication of MX2014011583A publication Critical patent/MX2014011583A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

Se proporcionan compuestos, composiciones y métodos que se relacionan a inhibidores de la proteína EWS-FLI1. Los compuestos tiene utilidad en el tratamiento de cánceres incluyendo la familia de tumores del Sarcoma de Ewing.
MX2014011583A 2012-04-12 2013-04-11 Metodos y composiciones para el tratamiento de la familia de tumores del sarcoma de ewing. MX2014011583A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261623349P 2012-04-12 2012-04-12
PCT/US2013/036234 WO2013155341A1 (en) 2012-04-12 2013-04-11 Methods and compositions for treating ewings sarcoma family of tumors

Publications (1)

Publication Number Publication Date
MX2014011583A true MX2014011583A (es) 2016-02-09

Family

ID=49328171

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014011583A MX2014011583A (es) 2012-04-12 2013-04-11 Metodos y composiciones para el tratamiento de la familia de tumores del sarcoma de ewing.

Country Status (13)

Country Link
US (2) US9290449B2 (es)
EP (1) EP2836481B1 (es)
JP (2) JP6130491B2 (es)
KR (1) KR102145835B1 (es)
CN (2) CN104395288B (es)
AU (2) AU2013245812B2 (es)
CA (1) CA2869513C (es)
HK (1) HK1207368A1 (es)
IL (1) IL234993B (es)
IN (1) IN2014DN09228A (es)
MX (1) MX2014011583A (es)
NZ (2) NZ723971A (es)
WO (1) WO2013155341A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8232310B2 (en) 2006-12-29 2012-07-31 Georgetown University Targeting of EWS-FLI1 as anti-tumor therapy
IN2014DN09228A (es) * 2012-04-12 2015-07-10 Univ Georgetown
US9511050B2 (en) 2013-10-24 2016-12-06 Georgetown University Methods and compositions for treating cancer
JP6654197B2 (ja) * 2014-10-09 2020-02-26 オンターナル セラピューティック インコーポレイテッドＯｎｃｔｅｒｎａｌ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． インドリノン化合物及びその使用
CN107530283A (zh) 2015-03-03 2018-01-02 奎尔波特股份有限公司 组合脂质体药物制剂
JP2018507227A (ja) 2015-03-03 2018-03-15 キュアポート インコーポレイテッド 二薬搭載リポソーム医薬製剤
ES2823190T3 (es) 2016-03-31 2021-05-06 Oncternal Therapeutics Inc Análogos de indolina y usos de los mismos
WO2018022771A1 (en) 2016-07-29 2018-02-01 Oncternal Therapeutics, Inc. Uses of indolinone compounds
EP3558266B1 (en) * 2016-12-21 2022-03-30 The Board of Regents of The University of Texas System Altertoxin ii as a selective inhibitor of ewing family of tumor cells
CN108186630B (zh) * 2017-12-18 2020-07-31 温州医科大学 靛红类似物在制备抗肿瘤药物中的应用
CN110870917B (zh) * 2018-09-03 2022-03-15 上海市第一人民医院 Ews或其上调剂在制备治疗糖尿病及防治糖尿病个体肿瘤发生的药物中的应用
US20230000823A1 (en) * 2021-06-09 2023-01-05 University Of Rochester Compounds and Methods for the Treatment of Acute Myelogenous Leukemia
CN114057626B (zh) * 2021-12-07 2023-06-30 山东第一医科大学(山东省医学科学院) 一种吲哚-2,3-二酮的衍生物和制备方法、抑制recql4特异性表达的抗肝癌药物
WO2023178040A2 (en) * 2022-03-13 2023-09-21 University Of Virginia Patent Foundation Inhibitors of ews-fli1

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1288436C (en) 1983-07-22 1991-09-03 David Paul Hesson Phenylquinolinecarboxylic acids and derivatives as antitumor agents
JP2002531498A (ja) 1998-12-04 2002-09-24 ニューロサーチ、アクティーゼルスカブ イオンチャネル活性剤としてのイサチン誘導体の使用方法
CN1155572C (zh) 2001-01-19 2004-06-30 中国人民解放军军事医学科学院毒物药物研究所 吲哚类衍生物及其抗肿瘤用途
US20030157486A1 (en) 2001-06-21 2003-08-21 Graff Jonathan M. Methods to identify signal sequences
EP1750776A2 (en) 2004-04-30 2007-02-14 Alnylam Pharmaceuticals Inc. Oligonucleotides comprising a c5-modified pyrimidine
AR056317A1 (es) 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc Compuestos de oxindol y composicion farmaceutica
US20090217390A1 (en) 2005-04-29 2009-08-27 Fernando Lecanda Cordero Non-human animal sarcoma model
WO2008046083A2 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Use of oxindole compounds as therapeutic agents
CA2711003C (en) * 2006-12-29 2017-02-21 Georgetown University Targeting of ews-fli1 as anti-tumor therapy
US8232310B2 (en) 2006-12-29 2012-07-31 Georgetown University Targeting of EWS-FLI1 as anti-tumor therapy
MX2009011281A (es) * 2007-04-20 2010-03-08 Univ New York State Res Found Benzimidazol y composiciones farmaceuticas del mismo.
US8377992B2 (en) * 2007-10-22 2013-02-19 The Wistar Institute TRBD-binding effectors and methods for using the same to modulate telomerase activity
US8710068B2 (en) 2009-01-19 2014-04-29 The Trustees Of The University Of Pennsylvania Method of treating cancer using a survivin inhibitor
WO2012078519A2 (en) 2010-12-06 2012-06-14 Numerate, Inc. 3-acylidene-2-oxoindole derivatives for inhibition of transglutaminase 2
IN2014DN09228A (es) 2012-04-12 2015-07-10 Univ Georgetown
CN103435606A (zh) 2013-08-22 2013-12-11 中国药科大学 CDK2与GSK3β双重抑制剂及用途
US9511050B2 (en) 2013-10-24 2016-12-06 Georgetown University Methods and compositions for treating cancer
JP6654197B2 (ja) 2014-10-09 2020-02-26 オンターナル セラピューティック インコーポレイテッドＯｎｃｔｅｒｎａｌ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． インドリノン化合物及びその使用

Also Published As

Publication number Publication date
KR20150007311A (ko) 2015-01-20
JP6130491B2 (ja) 2017-05-17
CN107011242B (zh) 2020-08-07
US20150051260A1 (en) 2015-02-19
AU2013245812A1 (en) 2014-11-13
AU2017201507B2 (en) 2018-10-04
JP2015512943A (ja) 2015-04-30
CN104395288B (zh) 2016-12-14
KR102145835B1 (ko) 2020-08-20
IL234993B (en) 2019-02-28
IN2014DN09228A (es) 2015-07-10
CA2869513A1 (en) 2013-10-17
CN107011242A (zh) 2017-08-04
CN104395288A (zh) 2015-03-04
EP2836481A1 (en) 2015-02-18
US20160159741A1 (en) 2016-06-09
JP6345301B2 (ja) 2018-06-20
NZ700612A (en) 2016-09-30
WO2013155341A1 (en) 2013-10-17
CA2869513C (en) 2020-07-07
AU2013245812A2 (en) 2014-11-20
US9714222B2 (en) 2017-07-25
EP2836481B1 (en) 2018-12-26
HK1207368A1 (en) 2016-01-29
US9290449B2 (en) 2016-03-22
NZ723971A (en) 2018-01-26
AU2017201507A1 (en) 2017-03-23
EP2836481A4 (en) 2015-11-18
AU2013245812B2 (en) 2017-04-06
JP2017141290A (ja) 2017-08-17

Similar Documents

Publication Publication Date Title
MX2014011583A (es) Metodos y composiciones para el tratamiento de la familia de tumores del sarcoma de ewing.
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
MX2016004678A (es) Composiciones para el tratamiento del cancer.
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
PH12014502772A1 (en) Substituted tricyclic compounds as fgfr inhibitors
UA115983C2 (uk) Інгібітори днк-пк
MX362215B (es) Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.
MX366804B (es) Translocaciones de la r-espondina y sus metodos de uso.
MX371108B (es) Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa.
PH12015500186A1 (en) Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
MX2015010125A (es) Derivados de piridazinona-amidas.
MX2015009209A (es) Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y metodos de tratamiento con los mismos.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MX357502B (es) Derivados de pirrolotriazinona.
PH12014501829A1 (en) Bicyclic pyrazinone derivatives
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
PH12015501088A1 (en) Dimeric compounds
MX2016001136A (es) Derivados de oxoquinazolinil-butanamida.
NZ628433A (en) Chitosan-derived compositions
MX364859B (es) Derivados de imidazopirazinona.
MX2016001536A (es) Derivados de urea de piperidinas.
MX2012013527A (es) Quinazolinas policíclicas, preparación de las mismas, y uso de las mismas.
EA201690376A1 (ru) Ингибиторы дезоксицитидинкиназы
MX342239B (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
MX2015000804A (es) Composiciones y metodos para tratar el sarcoma de ewing y otros trastornos relacionados con ews-fli1.

Legal Events

Date Code Title Description
FG Grant or registration